budigalimab
Sponsor Abbvie INC. · listed as ABBV
budigalimab is a drug asset sponsored by Abbvie INC., listed as ABBV. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jan 2027 (month precision, medium confidence), tied to trial NCT06109272. That trial is in Phase 2/3 and currently active not recruiting, studying Hepatocellular Carcinoma. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Other tracked assets in the same trials — NCT06109272: livmoniplimab; NCT06236438: livmoniplimab.
Trials for budigalimab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06109272 catalyst | Phase 2/3 | Active, not recruiting | 2027-01 | Experimental | AbbVie | Hepatocellular Carcinoma |
| NCT06236438 | Phase 2/3 | Recruiting | 2031-10 | Experimental | AbbVie | Non-Small Cell Lung Cancer |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More ABBV catalysts